[Mechanism of circZNF609 targeting miR-153 to regulate the proliferation and apoptosis of diffuse large B-cell lymphoma].

Objective: To investigate the molecular mechanism of circZNF609 targeting miR-153 to regulate the proliferation and apoptosis of diffuse large B-cell lymphoma. Methods: Fifty cases of lymphoma tissue from patients with diffuse large B-cell lymphoma who were diagnosed and treated in the First Affiliated Hospital of Zhengzhou University from July 2018 to December 2019 were collected. Thirty cases of normal lymph node tissues that were confirmed to be reactive hyperplasia by pathological diagnosis during the same period were selected as controls. Real time quantitative polymerase chain reaction (PCR) was used to detect the expression of circZNF609 in diffuse large B-cell lymphoma tissues and control hyperplasia lymph nodes. Diffuse large B-cell lymphoma OCI-LY19 cells were divided into control group (blank control), si-con group (transfected with siRNA control), si-ZNF609 group (transfected with circZNF609 siRNA), and si-ZNF609+ Anti-NC group (co-transfected with circZNF609 siRNA and inhibitor control) and si-ZNF609+ Anti-miR-153 group (co-transfected with circZNF609 siRNA and miR-153 inhibitor). Cell counting kit-8 (CCK-8) was used to detected proliferation, flow cytometry was used to detect cell cycle and apoptosis. Western blot was used to detect the protein expressions of C-caspase-3, cyclin D1, p21. The luciferase reporter system was used to identifie the relationship between circZNF609 and miR-153. Results: The expression level of circZNF609 in diffuse large B-cell lymphoma tissue was (1.44±0.22), higher than (0.37±0.14) in the control tissues (P<0.001). The cell survival rate of the si-ZNF609 group was (51.74±6.39)%, lower than (100.00±10.23)% of the control group and the (99.64±11.67)% of the si-con group (P<0.001). The proportion of cells in the G(0)/G(1) phase was (63.25±4.11)%, higher than (48.62±4.32)% of the control group and (47.12±3.20)% of the si-con group (P<0.001), the apoptosis rate was (13.36±1.42)%, higher than (3.65±0.47)% of the control group and (3.84±0.62)% of the si-con group (P<0.05). The expression levels of C-caspase-3 and p21 protein were (0.85±0.09) and (0.90±0.08), higher than (0.38±0.04) and (0.65±0.07) in the control group and (0.39±0.05) and (0.66±0.05) in the si-con group (P<0.001). The expression level of cyclin D1 protein was (0.40±0.03), lower than (0.52±0.06) of the control group and (0.53±0.04) of the si-con group (all P<0.001). CircZNF609 and miR-153 are mutually targeted. The cell survival rate of the si-ZNF609+ Anti-miR-153 group was (169.92±13.25)%, higher than (100.00±9.68)% of the si-ZNF609+ Anti-NC group (P<0.001), the ratio of cells in G(0)/G(1) phase and apoptosis rate were (52.01±3.62)% and (8.20±0.87)%, respectively, lower than (64.51±5.17)% and (14.03±1.17)% in the si-ZNF609+ Anti-NC group (P<0.001). The protein expression levels of C-caspase-3 and p21 were (0.42±0.06) and (0.52±0.06), lower than (0.80±0.07) and (0.92±0.10) of the si-ZNF609+ Anti-NC group (P<0.001). The protein expression level of cyclin D1 was (0.68±0.07), higher than (0.39±0.04) in the si-ZNF609+ Anti-NC group (P<0.001). Conclusion: Down-regulation of circZNF609 inhibits the proliferation of diffuse large B-cell lymphoma OCI-LY19 cells and induces apoptosis by targeting miR-153.目的： 探讨circZNF609靶向miR-153调控弥漫大B细胞淋巴瘤增殖和凋亡的分子机制。 方法： 选取2018年7月至2019年12月于郑州大学第一附属医院诊治的弥漫大B细胞淋巴瘤患者的淋巴瘤组织50例，选取同期经病理诊断证实为反应性增生的正常淋巴结组织30例作为对照。实时荧光定量PCR法检测弥漫性大B细胞淋巴瘤组织和对照组织中circZNF609的表达。弥漫大B细胞淋巴瘤OCI-LY19细胞分为Control组(空白对照)、si-con组(转染siRNA control)、si-ZNF609组(转染circZNF609 siRNA)、si-ZNF609+Anti-NC组(共转染circZNF609 siRNA和inhibitor control)和si-ZNF609+Anti-miR-153组(共转染circZNF609 siRNA和miR-153 inhibitor)。细胞计数试剂盒8法检测各组细胞的增殖情况，流式细胞术检测细胞周期、凋亡情况，Western blot检测C-caspase-3、cyclin D1、p21蛋白的表达水平，荧光素酶报告系统鉴定circZNF609与miR-153的关系。 结果： 弥漫大B细胞淋巴瘤组织中circZNF609的表达水平(1.44±0.22)高于对照组(0.37±0.12，P<0.001)。si-ZNF609组细胞存活率[(51.74±6.39)%]低于Control组和si-con组[分别为(100.00±10.23)%和(99.64±11.67)%，均P<0.001]，G(0)/G(1)期细胞比例[(63.25±4.11)%]高于Control组和si-con组[分别为(48.62±4.32)%和(47.12±3.20)%，均P<0.001]，细胞凋亡率[(13.36±1.42)%]高于Control组和si-con组[分别为(3.65±0.47)%和(3.84±0.62)%，均P<0.001]，C-caspase-3、p21蛋白表达水平(分别为0.85±0.09和0.90±0.08)高于Control组(分别为0.38±0.04和0.65±0.07)和si-con组(分别为0.39±0.05和0.66±0.05，均P<0.001)，cyclin D1蛋白表达水平(0.40±0.03)低于Control组和si-con组(分别为0.52±0.06和0.53±0.04，均P<0.001)。circZNF609和miR-153互为靶向关系。si-ZNF609+Anti-miR-153组细胞存活率[(169.92±13.25)%]高于si-ZNF609+Anti-NC组[(100.00±9.68)%，P<0.001]，细胞G(0)/G(1)期比例[(52.01±3.62)%]和凋亡率[(8.20±0.87)%]低于si-ZNF609+Anti-NC组[分别为(64.51±5.17)%和(14.03±1.17)%，均P<0.001]，C-caspase-3、p21蛋白表达水平(分别为0.42±0.06和0.52±0.06)低于si-ZNF609+Anti-NC组(分别为0.80±0.07和0.92±0.10，均P<0.001)，cyclin D1蛋白表达水平(0.68±0.07)高于si-ZNF609+Anti-NC组(0.39±0.04，P<0.05)。 结论： 下调circZNF609的表达靶向miR-153抑制弥漫大B细胞淋巴瘤OCI-LY19细胞增殖并诱导细胞凋亡。.